Barings LLC Raises Position in West Pharmaceutical Services Inc. (WST)

Barings LLC increased its holdings in West Pharmaceutical Services Inc. (NYSE:WST) by 100.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 26,065 shares of the medical instruments supplier’s stock after buying an additional 13,050 shares during the quarter. Barings LLC’s holdings in West Pharmaceutical Services were worth $3,218,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of WST. Integrated Investment Consultants LLC bought a new stake in West Pharmaceutical Services during the 2nd quarter valued at about $155,000. First Allied Advisory Services Inc. bought a new stake in West Pharmaceutical Services during the 2nd quarter valued at about $200,000. Alps Advisors Inc. bought a new stake in West Pharmaceutical Services during the 2nd quarter valued at about $206,000. Grandfield & Dodd LLC bought a new stake in West Pharmaceutical Services during the 2nd quarter valued at about $207,000. Finally, Wetherby Asset Management Inc. bought a new stake in West Pharmaceutical Services during the 2nd quarter valued at about $223,000. Institutional investors own 93.64% of the company’s stock.

In other news, SVP Karen Flynn sold 20,458 shares of West Pharmaceutical Services stock in a transaction that occurred on Tuesday, August 7th. The shares were sold at an average price of $116.23, for a total value of $2,377,833.34. Following the completion of the sale, the senior vice president now directly owns 31,051 shares in the company, valued at $3,609,057.73. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.70% of the company’s stock.



A number of research firms have weighed in on WST. Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $123.00 price objective for the company in a research note on Tuesday, July 31st. ValuEngine upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Wednesday, October 17th.

Shares of WST stock opened at $101.32 on Tuesday. West Pharmaceutical Services Inc. has a 52 week low of $82.74 and a 52 week high of $125.09. The company has a market capitalization of $7.44 billion, a PE ratio of 36.45, a P/E/G ratio of 3.46 and a beta of 1.16. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.67 and a quick ratio of 1.94.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, October 25th. The medical instruments supplier reported $0.76 EPS for the quarter, topping analysts’ consensus estimates of $0.70 by $0.06. West Pharmaceutical Services had a net margin of 9.06% and a return on equity of 15.97%. The firm had revenue of $431.70 million during the quarter, compared to analyst estimates of $427.55 million. Equities research analysts anticipate that West Pharmaceutical Services Inc. will post 2.8 EPS for the current fiscal year.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Featured Article: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply